Every Form 4 that IDEAYA Biosciences, Inc. (IDYA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IDYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDYA filings page.
IDEAYA Biosciences’ Chief Accounting Officer Andres Ruiz Briseno exercised stock options and sold shares in a pre-planned transaction. On July 7, 2026, he exercised 9,550 stock options at $12.86 per share to acquire common stock, then sold 9,550 common shares in open-market trades at a weighted average price of about $40.01 per share. The sale was executed under his Rule 10b5-1 trading plan adopted on December 19, 2025. Following these transactions, he directly owned 26,466 shares of IDEAYA Biosciences common stock.
IDEAYA Biosciences director Wendy L. Yarno received a grant of stock options for 20,000 shares of common stock at an exercise price of $30.57 per share. The options vest 100% on the earlier of one year from grant or immediately before the next Annual Meeting, subject to continued Board service, and expire on June 16, 2036.
IDEAYA Biosciences director Jeffrey Stein received a grant of stock options to acquire 20,000 shares of common stock at an exercise price of $30.57 per share. These options expire on June 16, 2036 and are intended as equity-based compensation.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting following the grant date, provided he continues serving on the board through the vesting date.
IDEAYA Biosciences director Terry J. Rosen received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036. According to the footnote, 100% of the option vests on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if he continues serving on the Board until that vesting date.
IDEAYA Biosciences director Scott W. Morrison received a grant of stock options for 20,000 shares of Common Stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036. All 20,000 shares vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if he remains on the Board through that date.
This is a compensation-related award, not an open-market purchase or sale, and leaves him with 20,000 derivative securities reported after the transaction.
IDEAYA Biosciences director Catherine J. Mackey received a stock option grant covering 20,000 shares of Common Stock. The option has an exercise price of $30.57 per share and expires on June 16, 2036. All 20,000 option shares vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if she continues serving on the Board.
IDEAYA Biosciences, Inc. director Malcolm Garret Hampton received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036.
All 20,000 options vest in full on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting following the grant, as long as he continues serving on the board through the vesting date. This filing reflects a compensation-related award rather than an open-market trade.
IDEAYA Biosciences director Jeffrey Stein bought more company stock in the open market. On March 2, 2026, he purchased 50,000 shares of common stock in open-market transactions at a weighted average price of $32.9578 per share, with individual trades executed between $32.743 and $33.1999.
Following this purchase, he directly owns 54,281 common shares. An additional 3,363 shares are reported as held indirectly by his son.
IDEAYA Biosciences Chief Financial Officer receives new stock option grant. On January 30, 2026, CFO Joshua Bleharski was granted a stock option to purchase 170,000 shares of IDEAYA common stock at an exercise price of $32.19 per share, expiring on January 30, 2036.
According to the vesting terms, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences granted its Chief Scientific Officer, Michael Anthony White, a stock option covering 190,000 shares of common stock on January 30, 2026. The option has an exercise price of $32.19 per share and is held directly by him.
According to the vesting terms, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years. This schedule makes the option fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences’ Chief Medical Officer, Darrin Beaupre, reported a new stock option grant. On January 30, 2026, he received a stock option to buy 175,000 shares of IDEAYA common stock at an exercise price of $32.19 per share, expiring on January 30, 2036.
The option vests over four years starting from January 1, 2026: 25% of the shares vest on the first anniversary, then 1/48th of the total shares vest monthly so that the grant is fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences, Inc. granted a new equity award to its Chief Commercial Officer, Stuart Dorman. On January 30, 2026, he received a stock option for 155,000 shares of common stock with an exercise price of $32.19 per share.
According to the vesting schedule, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences President and CEO Yujiro Hata received a grant of stock options reported as of January 30, 2026. The award covers 600,000 options to buy IDEAYA common stock at an exercise price of $32.19 per share.
According to the vesting terms, 25% of the options vest on the first anniversary of January 1, 2026, and the remaining portion vests in equal monthly installments over the following three years, so the grant becomes fully vested on the fourth anniversary of that date.
IDEAYA Biosciences SVP and General Counsel Douglas B. Snyder reported routine equity awards and employee share purchases. On 05/30/2025 and 11/28/2025, he acquired 1,039 and 1,041 shares of common stock, respectively, at $16.9065 per share under the company’s Employee Stock Purchase Plan, bringing his directly held common stock to 2,080 shares.
On 01/30/2026, he received a stock option for 130,000 shares of common stock at an exercise price of $32.19. The option vests 25% on the first anniversary of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years until fully vested on the fourth anniversary.
IDEAYA Biosciences officer Andres Ruiz Briseno reported new equity awards and share acquisitions. He acquired 682 common shares on 11/29/2024 at $23.256 and 1,253 shares on 11/28/2025 at $16.9065 under the company’s Employee Stock Purchase Plan, bringing his direct holdings to 26,466 shares.
He was also granted a stock option for 80,000 shares of common stock at an exercise price of $32.19 on 01/30/2026. According to the grant terms, 25% of the option vests on the first anniversary of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years.